

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61M 16/00, A61B 5/087		A1	(11) International Publication Number: WO 99/61088
			(43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/AU99/00386		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 21 May 1999 (21.05.99)			
(30) Priority Data: PP 3663 22 May 1998 (22.05.98) AU			
(71) Applicant (for all designated States except US): RESMED LIMITED [AU/AU]; 97 Waterloo Road, North Ryde, NSW 2113 (AU).			
(72) Inventor; and		Published	
(75) Inventor/Applicant (for US only): BERTHON-JONES, Michael [AU/AU]; 7 Leonay Parade, Leonay, NSW 2750 (AU).		With international search report.	
(74) Agent: SPRUSON & FERGUSON; G.P.O Box 3898, Sydney, NSW 2001 (AU).			

(54) Title: VENTILATORY ASSISTANCE FOR TREATMENT OF CARDIAC FAILURE AND CHEYNE-STOKES BREATHING



(57) Abstract

Method and apparatus for the treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea are disclosed. A subject is provided with ventilatory support, for example positive pressure ventilatory support using a blower and mask. Respiratory airflow is determined. From the respiratory airflow are derived a measure of instantaneous ventilation (for example half the absolute value of the respiratory airflow) and a measure of longterm average ventilation (for example the instantaneous ventilation low pass filtered with a 100 second time constant). A target ventilation is taken as 95 % of the longterm average ventilation. The instantaneous ventilation is fed as the input signal to a clipped integral controller, with the target ventilation as the reference signal. The output of the controller determines the degree of ventilatory support. Clipping is typically to between half and double the degree of support that would do all the respiratory work. A third measure of ventilation, for example instantaneous ventilation low pass filtered with a time constant of 5 seconds, is calculated. Ventilatory support is in phase with the subject's respiratory airflow to the fuzzy extent that this ventilation is above target, and at a preset rate conversely.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**VENTILATORY ASSISTANCE FOR TREATMENT OF CARDIAC FAILURE
AND CHEYNE-STOKES BREATHING**

FIELD OF THE INVENTION

5 The invention relates to methods and apparatus for the provision of positive pressure ventilatory assistance for patients with cardiac failure or Cheyne-Stokes breathing from any cause, including central sleep apnea, cardiac failure or stroke.

EXPLANATION OF TERMS

10 In this specification, respiratory airflow is intended to refer to the instantaneous flow of gas into or out of the lungs. The term "average" is intended to mean any measure of central tendency or the result of any low pass filtering operation. Ventilatory support is intended to mean any procedure which has a similar effect as the respiratory muscles, particularly the supply of breathable gas under varying positive pressure to the airway via

15 a nosemask, face mask, endotracheal tube, tracheotomy tube, or the like, but also including other procedures such as negative pressure ventilation, cuirasse, iron lung, external chest compression, or rocking bed ventilation. According to common usage, ventilation can mean either a procedure, as in the expression "positive pressure ventilation", or a measure of average respiratory airflow over a period of time.

20 Instantaneous ventilation is intended to mean the volume inspired over a short period of time less than several seconds. Equally it can be calculated as the volume expired over such a period, or it can be the average of the two. For example, measures of instantaneous ventilation would include half the average of the absolute value of the respiratory airflow, calculated over a time interval short compared with several seconds, or half the absolute

25 value of the respiratory airflow, low pass filtered with a time constant short compared with several seconds. For technical reasons to be explained below, in the best embodiment, instantaneous ventilation is taken as half the absolute value of the instantaneous respiratory airflow, ie averaged over an arbitrarily short period of time. However, it is not intended that the invention is limited to calculating instantaneous

30 ventilation in this way.

The term "varying A inversely with B" is intended in the broad sense of increasing A if B is decreasing, and decreasing A if B is increasing.

5 The term "servo-controller" here refers to a feedback controller accepting an input, or controlled, variable (for example actual measured ventilation) and a reference quantity (for example a desired or target ventilation), and producing an output (for example the settings of a ventilator) which is used to subsequently bring the value of the input (controlled) variable towards the value of the reference variable.

10 The term "oppose" can include reduce, limit, dampen, or prevent.

The terms "recent average ventilation" and "longterm average ventilation" are to be understood to be equivalents.

15 **BACKGROUND OF THE INVENTION**

Patients with cardiac failure have reduced cardiac ejection fraction, are typically very breathless, and often wake at night with extreme breathlessness called paroxysmal nocturnal dyspnea, due to accumulation of fluid in the lungs.

20 Patients with cardiac failure also often have Cheyne-Stokes breathing, particularly during sleep. Cheyne-Stokes breathing is an abnormal limit cycle instability of the patient's respiratory controller in which there are rhythmic alternating periods of waxing and waning ventilation, causing repetitive deoxygenation and reoxygenation of the arterial blood. The cause of the waxing and waning of ventilation is not entirely clear, 25 but there is an increase in chemoreceptor gain [*Wilcox I et al. Ventilatory control in patients with sleep apnoea and left ventricular dysfunction: comparison of obstructive and central sleep apnoea. 1998; 11:7-13*], possibly related to stimuli arising in the heart or lungs, a change in the chemoreceptor set point leading to overventilation and alkalosis in the awake state with apneas during sleep, and an increase in circulation time leading to 30 delays between ventilation and chemoreception [*Naughton M et al. Role of hyperventilation in the pathogenesis of central sleep apneas in patients with congestive heart failure. Am Rev Respir Dis 1993; 148:330-338*]. Cheyne-Stokes breathing is

associated with high mortality [*Andreas et al. Cheyne-Stokes respiration and prognosis in congestive heart failure. Am J Cardiol 1996; 78:1260-1264*]. It is possible that it is harmful because of the repetitive hypoxia, which will lead to hypoxic pulmonary vasoconstriction and high right heart afterload, and to increased sympathetic activity, 5 systemic vasoconstriction and high left heart afterload. It may also be harmful because of repetitive alkalosis during the waxing period of the cycle. Finally, in some patients it is associated with repetitive arousal from sleep, which causes severe sleep disruption, increased sympathetic activity, and increased afterload.

10 Continuous positive airway pressure (CPAP) has been used for decades for the emergency treatment of pulmonary oedema, and is more recently being used longterm during sleep for the treatment of cardiac failure. Nasal CPAP leads to an improvement in cardiac output and ejection fraction, and an improvement in quality of life [*Naughton MT et al, Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure. Am J Respir Crit Care Med 1995; 151:92-97*], and a reduction in sympathetic nervous system activity [*Naughton MT et al, Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 1995; 152:473-479*]. The precise mechanism of action is unclear. Making the alveolar pressure and right atrial pressure positive with respect to the inferior 15 vena caval pressure, and making the left ventricular pressure more positive with respect to abdominal aortic pressure, will tend to dry the lungs, improve gas exchange, relieve paroxysmal nocturnal dyspnea, reduce reflex pulmonary vasoconstriction, reduce sympathetic activity and reduce cardiac afterload via multiple complex mechanisms. Making the alveolar pressure and right atrial pressure positive with respect to the inferior vena caval pressure, and making the left ventricular pressure more positive with respect to abdominal aortic pressure, will tend to dry the lungs, improve gas exchange, relieve 20 paroxysmal nocturnal dyspnea, reduce reflex pulmonary vasoconstriction, reduce sympathetic activity and reduce cardiac afterload via multiple complex mechanisms. Standard nasal CPAP masks may also help stabilize Cheyne-Stokes breathing, because the effective ventilation cannot exceed the fresh gas flow, which is in turn set by the exhaust flow. Finally, many patients with cardiac failure also have coexisting obstructive 25 sleep apnea, which worsens cardiac failure but is treated by nasal CPAP.

30 Unfortunately, despite excellent effectiveness, nasal CPAP is often poorly tolerated by patients with cardiac failure, particularly early on in treatment, and it has not become widely used. The reasons for the poor tolerance are unknown. In addition, nasal CPAP reduces, but unfortunately does not immediately suppress the Cheyne-Stokes

breathing [*Naughton MT et al. Effect of continuous positive airway pressure on central sleep apnea and nocturnal PCO₂ in heart failure. Am J Respir Crit Care Med 1994; 150:1598-1604.*

5 Various other approaches using known methods of ventilatory assistance suggest themselves in order to provide the same benefit as CPAP while also reducing either respiratory work or Cheyne-Stokes breathing or both. Unfortunately no known device is completely satisfactory, either because of discomfort, overventilation, or both. For example, Fig. 1 shows persistent Cheyne-Stokes breathing in a patient with cardiac failure
10 being treated with bilevel ventilatory support with timed backup. The subject is in stage 3 non-REM sleep. The polygraph tracings are arterial haemoglobin oxygen saturation (top tracing), chest wall movement (middle tracing), and mask pressure (bottom tracing). The Cheyne-Stokes breathing persists. Note, in the middle trace, the cyclical waxing and waning of the amplitude of chest wall movement, indicating periods of overbreathing and
15 underbreathing, and resultant regular decreases in arterial haemoglobin oxygen saturation despite the ventilatory support.

Many classes of ventilator, far from increasing comfort, actually decrease comfort. Volume cycled ventilators (regardless of the trigger variable) and time triggered
20 ventilators (regardless of the cycling variable) often show very poor synchronization between machine and patient, which is distressing to the patient. Volume cycled ventilators and high impedance pressure cycled ventilators do not permit the patient to increase or decrease ventilation voluntarily, which is also distressing to the patient. Subjects with Cheyne-Stokes breathing may be particularly distressed by inadequate
25 volume settings, due to their high chemoreceptor gain.

Another serious problem is overventilation. Most ventilatory assistance devices are designed to replace or augment respiratory effort in subjects with respiratory failure or insufficiency, and by design, cause a nett increase in mean ventilation above the subject's spontaneous mean ventilation. Unfortunately, in subjects who are not initially acidotic, such as the subjects of the present discussion, ventilatory assistance causes or exacerbates hypcapnia and alkalosis, leading in turn to reflex upper airway and particularly vocal

cord closure during sleep [Jounieux *et al.* *Effects of nasal positive pressure hyperventilation on the glottis in normal sleeping subjects. J Appl Physiol 1995; 79:186-193*]. Far from treating the disordered breathing, excessive ventilatory support will actually produce closed airway central apneas. Some ventilatory assistance devices, in an attempt to provide increased comfort, support ventilation specifically during periods of increased patient effort (for example proportional assist ventilation and all classes of ventilators with spontaneous triggering without timed backup). This will yet further enhance any tendency to cyclically disordered breathing during sleep. Similarly, in the case of volume cycled ventilators, awake comfort can usually only be achieved by overventilation, with alkalosis and consequent airway closure in sleep. Overventilation and alkalosis can sometimes be extremely dangerous. Indeed, in patients with cardiac failure and acute pulmonary edema, bilevel ventilation with fixed high pressure swings appears to be associated with an increased risk of myocardial infarction [Mehta *et al.* *Randomized prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary oedema. Crit Care Med 1997; 25:620-628*].

Another approach to the overventilation problem is to provide ventilatory assistance only during periods of reduced subject efforts, for example by triggering the ventilator only if the subject has not produced an inspiration for at least a specified period of time. This is unsatisfactory for three reasons. Firstly, during spontaneous breathing, this solution will not provide any increase in comfort over normal CPAP, and this was one of the problems to be solved. Secondly, the sudden abrupt increase in support at the onset of an apnea will in general tend to awaken the patient from sleep, leading to both sleep fragmentation and transient overventilation leading to further sleep disordered breathing. Thirdly, as with all previous methods, it is difficult to set the level of support during periods of central apnea high enough to prevent Cheyne-Stokes breathing or central sleep apneas, but not so high as to produce airway closure.

A more satisfactory approach is described in commonly owned International Publication No. WO 98/12965, in which a target ventilation is selected, and the degree of support is automatically adjusted to servo-control the measured ventilation to at least equal the target ventilation. A minimum level of support, chosen not to produce

overventilation, is provided for comfort during awake breathing. If the target ventilation is chosen to be slightly less than the eupneic ventilation, then Cheyne-Stokes breathing and central sleep apnea may be prevented without the risk of overventilation. Because the degree of support increases smoothly as the subject's own efforts decrease, there is no
5 explosively sudden increase in support which might wake the patient. However, there are two limitations to having a fixed target ventilation. Firstly, the target ventilation needs to be chosen, and this can be difficult: too high a value will lead to overventilation, while too low a value will permit some residual Cheyne-Stokes breathing. Secondly, due to changes in metabolic rate with restlessness, sleep state, body temperature, meals, etc, the
10 ideal target ventilation is not constant.

In summary, longterm nasal CPAP therapy is of known benefit in the treatment of cardiac failure, but is poorly tolerated, and does not usually or completely alleviate Cheyne-Stokes breathing or central sleep apnea, at least initially. Attempting to increase
15 tolerance and/or treat the disordered breathing using ventilatory support is difficult, or only partially successful, depending on the device used, because of the need to avoid overventilation. Very similar comments apply to the treatment of Cheyne-Stokes breathing and/or central sleep apnea due to many other causes in such as stroke or acromegaly.

20

DISCLOSURE OF THE INVENTION

The present invention is directed to providing a subject with cardiac failure positive airway pressure therapy, to achieve an improvement in the symptoms and signs of cardiac failure similar to that afforded by CPAP, by modulating the mask pressure in
25 such a way as to provide increased comfort without overventilation, hypocapnia, alkalosis, or upper airway closure. The present invention is further directed to the stabilization or prevention of Cheyne-Stokes breathing or central sleep apnea from many causes.

30

The invention discloses a method for treatment of cardiac failure, Cheyne-Stokes breathing, or central sleep apnea, comprising the steps of:
providing a subject with ventilatory support;

deriving a measure of instantaneous ventilation; and
adjusting the degree of ventilatory support to oppose short term changes in said measure of instantaneous ventilation, but permitting longterm changes in said measure of instantaneous ventilation.

5

The invention further discloses apparatus for the treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising:

a device for providing ventilatory support of controllable magnitude;
means for deriving a signal indicative of instantaneous ventilation of a subject;

10 and

a servo-controller operable to control the degree of ventilatory support provided by said ventilatory support device to oppose short-term changes in said measure of instantaneous ventilation, but permit longterm changes in said measure of instantaneous ventilation.

15

The invention discloses a method for treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising the steps of:

providing a subject with ventilatory support;
deriving a measure of the subject's instantaneous ventilation; and

20 adjusting the degree of ventilatory support to reduce changes in said measure of instantaneous ventilation over a timescale similar to that of the waxing-waning cycle of untreated Cheyne-Stokes breathing or central sleep apnea, while allowing changes in said measure of instantaneous ventilation over a timescale much longer than said waxing-waning cycle.

25

The invention further discloses a method for treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising the steps of:

providing a subject with ventilatory support;
deriving a measure of the subject's instantaneous ventilation;
30 deriving a measure of the subject's longterm average ventilation;
setting the controlled variable of a servo-controller to a function of said measure of the subject's instantaneous ventilation;

setting the reference variable of said servo-controller to a measure of the subject's longterm average ventilation; and

adjusting the magnitude of said ventilatory support in accordance with the output of said servo-controller.

5

The invention yet further discloses a method for treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising the steps of:

providing a subject with ventilatory support;

deriving a measure of the subject's instantaneous ventilation;

10 high pass filtering said measure of the subject's instantaneous ventilation; and

adjusting the degree of said ventilatory support inversely with said high pass filtered measure of the subject's instantaneous ventilation.

The invention also discloses a method for the treatment of cardiac failure,

15 Cheyne-Stokes breathing or central sleep apnea, comprising the steps of: ...

providing a subject with positive pressure ventilatory support, with controllable amplitude and rate;

deriving a measure of the subject's instantaneous ventilation;

adjusting said amplitude of positive pressure by:

20 (a) low pass filtering said measure of instantaneous ventilation to derive a measure of recent average ventilation;

(b) setting a target ventilation equal to a fraction of said measure of recent average ventilation; and

(c) servo-controlling said measure of instantaneous ventilation to at least equal the target ventilation, by adjusting the degree of ventilatory support;

25 and

continuously adjusting said rate by:

30 (a) to the extent that the instantaneous ventilation equals or exceeds said target ventilation, modulating said positive pressure in phase with respiratory airflow; and

(b) to the extent that the instantaneous ventilation is less than said target ventilation, modulating said positive pressure at a pre-set rate.

The invention further discloses apparatus for treatment of cardiac failure,
5 Cheyne-Stokes breathing or central sleep apnea, comprising:

a controllable source of breathable gas at positive pressure;

means for delivering said breathable gas at positive pressure to a subject's airway;

means for deriving a measure of the subject's instantaneous ventilation; and

10 a servo-controller for adjusting the degree of ventilatory support to reduce changes in said measure of instantaneous ventilation over a timescale similar to that of the waxing-waning cycle of untreated Cheyne-Stokes breathing or central sleep apnea, while allowing changes in said measure of instantaneous ventilation over a timescale much longer than said waxing-waning cycle.

15

The invention yet further discloses apparatus for treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising:

a controllable source of breathable gas at positive pressure;

means for delivering said breathable gas at positive pressure to a subject's
20 airway;

means for deriving a measure of the subject's instantaneous ventilation;

means for deriving a measure of the subject's longterm average ventilation;

means for deriving a target ventilation as a function of said measure of the subject's longterm average ventilation;

25 a servo-controller, whose input variable is a function of said measure of the subject's instantaneous ventilation, and whose reference variable is said target ventilation: and

means for adjusting the magnitude of said ventilatory support according to the output of the servo-controller.

30

The invention also discloses apparatus for the treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising:

ventilator means for providing ventilatory support with controllable amplitude and rate;

sensor and processing means for deriving a signal indicative of instantaneous ventilation of a subject; and

5 servo-control means operable to adjust the amplitude of the pressure support by low pass filtering said instantaneous ventilation signal to derive a measure of recent average ventilation, setting a target ventilation equal to a fraction of said measure of recent average ventilation, and servo-controlling said measure of instantaneous ventilation to at least equal the target ventilation, and further operable to continuously adjust said rate
10 by modulating said positive pressure in phase with respiratory airflow to the extent that the instantaneous ventilation equals or exceeds said target ventilation, and modulating said positive pressure at a pre-set rate to the extent that the instantaneous ventilation is less than said target ventilation.

15 Embodiments of the invention provide a degree of ventilatory support which many subjects will perceive as very comfortable. Cheyne-Stokes breathing is reduced or eliminated. Unlike the case of prior art taught in International Publication No. WO 98/12965, the physician is not required to estimate or empirically determine a target ventilation, as this is done automatically. The risk of overventilating the subject
20 and causing alkalosis or airway closure is also reduced.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the present invention will now be described, by way of example only, with reference to the accompanying drawings.

25

Fig. 1 is a plot of a 10 minute excerpt from a polygraph tracing from a sleeping patient with cardiac failure, during treatment with prior art bilevel ventilation in Stage III non-REM sleep.

30

Fig. 2 is a schematic diagram of ventilation apparatus embodying the invention.

Fig. 3 is a plot of a pressure waveform template. The horizontal axis ϕ is the phase in the respiratory cycle, measured in revolutions, such that 0 is start of inspiration, 0.5 revolutions is start of expiration, and 1 revolution is end of expiration.

5 Fig. 4 is a plot of a 10 minute excerpt from a polygraph tracing from the subject from Fig.1, also in Stage III non-REM sleep, being treated by an embodiment of the present invention. Cheyne-Stokes breathing has been eliminated.

10 Fig. 5 is a schematic diagram showing respiratory airflow during Cheyne-Stokes breathing, and various calculated quantities, including two measures of "instantaneous" ventilation, "recent average" ventilation, and "target" ventilation with time.

15 Fig. 6 is a schematic diagram showing, for a preferred embodiment, the expected increase in degree of ventilatory support in response to a sudden cessation of all respiratory efforts by the subject with time.

20 Fig. 7 is a schematic diagram showing, for the preferred embodiment, how the degree of assistance will remain at the minimum level if the subject's ventilation steadily decreases over a very long time period.

DESCRIPTION OF PREFERRED EMBODIMENTS AND BEST MODE

A ventilator embodying one form of the invention is shown in Fig. 2 in which a blower 10 supplies breathable gas to a mask 11 for communication with a subject's airway via a delivery tube 12 and exhausting to atmosphere via an exhaust 13. Airflow at the mask 11 is measured using a pneumotachograph 14 and a differential pressure transducer 15. The mask flow signal 22 from the transducer 15 is sampled by a microcontroller 16. Mask pressure is measured at port 17 using a pressure transducer 18. The pressure signal 24 from the transducer 18 is also sampled by the microcontroller 16. The microcontroller 16 sends an instantaneous mask pressure request signal 26 to a servo 19, which compares the pressure request signal (ie. the desired pressure signal) 26 with the actual pressure signal 24 from the transducer 18 to control a motor 20 driving the blower 10. The microcontroller 16 settings can be adjusted via a serial port 21.

It is to be understood that the mask could equally be replaced with a tracheotomy tube, endotracheal tube, nasal pillows, or other means of making a sealed connection between the air delivery means and the subject's airway.

5

The steps performed by the microcontroller 16 to determine the requested mask pressure will now be described.

The microcontroller 16 accepts the mask airflow and pressure signals 22,24, and
10 from said signals determines the instantaneous flow through any leak between the mask and subject, by any convenient method. For example, the conductance of the leak may be estimated as the instantaneous mask airflow low pass filtered with a time constant of 10 seconds, divided by the similarly low pass filtered square root of the instantaneous mask pressure, and the instantaneous leakage flow may be calculated as said conductance
15 multiplied by the square root of the instantaneous mask pressure. Respiratory airflow is then calculated as the instantaneous mask airflow minus said instantaneous leakage flow.

Having determined the respiratory airflow, the microcontroller 16 now determines the subject's recent average absolute respiratory airflow as the 100 second low
20 pass filtered absolute value of the respiratory airflow. The 100 second time constant is chosen because it is long compared with the lung-chemoreceptor delay in patients with Cheyne-Stokes breathing or central sleep apnea (typically up to 20 sec), and somewhat longer than the cycle time of typical Cheyne-Stokes breathing of about 60 seconds. Longer time constants will in principle give better suppression of Cheyne-Stokes
25 breathing as long as the subject's chemoreceptor set-point is constant, but will take longer to settle at sleep onset and longer to track changes in set-point. The term "recent average" is used in the sense of recent compared with an entire night's sleep. However, compared with "instantaneous" ventilation, which is measured on a timescale of a single breath or less, the 100 second low pass filtered absolute value of the respiratory airflow is, of
30 course, a longterm average.

A target absolute respiratory airflow is then calculated as 95% of said recent average absolute respiratory airflow. Larger values can result in positive feedback leading to drift in the ventilation, while smaller values will permit residual Cheyne-Stokes breathing.

5

Fig. 5 shows the above steps schematically. The top tracing in the figure is respiratory airflow. The second tracing, labelled "Instantaneous Ventilation 1", is the absolute value of the respiratory airflow. The bottom tracing shows, schematically, another measure of instantaneous ventilation, labelled "Instantaneous Ventilation 2", which is Instantaneous Ventilation 1 low pass filtered with a time constant of a few breaths. Instantaneous Ventilation 2, as a measure of ventilation, could equally be subsequently used as an input to a servo-controller to adjust the degree of ventilatory support, although this may not be the optimal approach. The bottom tracing also shows schematically the recent average ventilation and the target ventilation.

15

Having calculated the target ventilation, a microcontroller now calculates a mask pressure modulation amplitude A. The object of this step is to modulate the pressure modulation amplitude in a direction opposite to changes in the output from the subject's own respiratory controller, providing more support when the subject is making shallow efforts, and less support when the subject is making strong efforts, thus stabilizing the subject's breathing. It is necessary in this step that the servo-controller should have a delay that is very short compared with the delay in the subject's own respiratory controller; a long delay would further destabilize the subject's breathing. If a proportional or integral controller were fed with a measure of the subject's ventilation taken over many seconds, for example, longer than the case of "Instantaneous Ventilation 2" in Fig. 5, the controller delay would be too long. Conversely, if a proportional controller were supplied with the rectified instantaneous respiratory airflow (as in Instantaneous Ventilation 1 in Fig. 5), then the controller output would be varying out of phase with the subject's breathing efforts, and the subject would perceive an increase in the work of breathing. In the present implementation, a clipped integral controller is fed with Instantaneous Ventilation 1, the absolute value of the respiratory airflow. The process of integration

both smooths and delays within-breath changes in the amplitude A, so that the subject does not perceive any increase in work of breathing. A suitable algorithm is as follows:

5 calculate an error term e equal to the instantaneous absolute respiratory airflow minus the target absolute respiratory airflow;

set the pressure modulation amplitude A equal to

$$A = \int G e dt$$

10

where G is the controller integral gain, typically $-0.3 \text{ cmH}_2\text{O L/min per second}$, and the integral A is clipped to a convenient range such as $3-12 \text{ cmH}_2\text{O}$.

15

Larger values of G can result in positive feedback in the controller. Smaller values will permit some residual untreated Cheyne-Stokes breathing or central sleep apnea. The minimum amplitude ($3 \text{ cmH}_2\text{O}$ being a suitable value suitable for most subjects) is chosen to be of the order of 50% of the estimated amplitude required to perform all the respiratory work of the subject in the steady state. A minimum value of 20 this order of magnitude provides much improvement in comfort over a minimum value of zero. The maximum amplitude ($12 \text{ cmH}_2\text{O}$ being typical) is chosen to be approximately double the amplitude that would perform all the respiratory work of the subject (and therefore sufficient to support the subject's breathing if they cease making any efforts) but less than a value that would be uncomfortable or dangerous.

25

The microcontroller 16 then determines the instantaneous phase Φ in the respiratory cycle from the instantaneous respiratory airflow, looks up a pressure waveform template $\Pi(\Phi)$ and sets the instantaneous mask pressure to:

30

$$P_{mask} = P_0 + A \Pi(\Phi)$$

where P_0 is an end expiratory pressure, typically 5-10 cmH₂O, but chosen to be sufficient to treat any underlying obstructive sleep apnea syndrome.

In a simplest embodiment, the respiratory phase Φ is taken as bivalued: inspiratory if the instantaneous respiratory airflow is positive, and expiratory otherwise, and $\Pi(\Phi)$ is unity for inspiration and zero for expiration. If phase has been expiratory for more than a set time, chosen to be slightly longer than the subject's normal expiratory time, then the phase is switched to inspiratory.

In another embodiment, Φ is a continuous variable from zero to 1 revolution, and the pressure waveform template $\Pi(\Phi)$ is as shown in Fig 3. In this embodiment, the microcontroller determines Φ using the following fuzzy logic rules:

1. If the airflow is zero and increasing fast then the phase is 0 revolutions.
2. If the airflow is large positive and steady then the phase is 0.25 revolutions.
3. If the airflow is zero and falling fast, then the phase is 0.5 revolutions.
4. If the airflow is large negative and steady then the phase is 0.75 revolutions.
5. If the airflow is zero and steady and the 5 second low pass filtered absolute value of the respiratory airflow is large then the phase is 0.9 revolutions.
6. If the airflow is positive and the phase is expiratory, then the phase is 0 revolutions.
7. If the airflow is negative and the phase is inspiratory, then the phase is 0.5 revolutions.
8. If the 5 second low pass filtered absolute value of the respiratory airflow is small, the phase in the respiratory cycle is increasing at a fixed rate equal to the subject's expected respiratory rate.
9. If the 5 second low pass filtered absolute value of the respiratory airflow is large, the phase in the respiratory cycle is increasing at a steady rate

equal to the existing rate of change of phase, low pass filtered with a time constant of 20 seconds.

5 The fuzzy extent to which the airflow is "large", "steady", etc can be determined with suitable membership functions.

Rules 1-4 estimate the phase directly from the instantaneous respiratory airflow. Rule 5 permits an expiratory pause, whose length may be long if the subject has recently been breathing adequately, and short or zero if the subject is not breathing. This is 10 particularly appropriate for subjects with Cheyne-Stokes breathing, because an expiratory pause should not be permitted if the subject is apneic. Rules 6-7 provide for quick resynchronization in the event that the subject breathes irregularly. Rule 8 provides the equivalent of a timed backup, in which, to the extent that the subject has stopped breathing or is not adequately breathing, the ventilator will cycle at a suitable fixed rate. 15 Rule 9 provides that to the extent that the subject is breathing adequately, the ventilator will tend to track the subject's recent average respiratory rate. This is particularly appropriate in subjects with cardiac failure and Cheyne-Stokes breathing, whose respiratory rate tends to be extremely steady despite rhythmic changes in amplitude.

20 An effect of the changing degree of activation of rules 8 and 9 is that, to the fuzzy extent that the instantaneous ventilation equals or exceeds the target ventilation, ventilatory support will be provided in phase with the subject's own respiratory efforts, and to the extent that the instantaneous ventilation is less than the target ventilation, ventilatory support will be provided at a pre-set rate.

25

In an elaboration of this embodiment, the weighting of rules 1-6 can be made proportional to the fuzzy extent that the instantaneous ventilation is large compared with the target ventilation. This strengthens the tendency for the device to act as described in the previous paragraph.

30

In a further elaboration, the weighting of rules 1-6 and also of rule 9 can be made smaller, and the weighting of rule 8 can be larger, if the leak is large, or if there is a

sudden change in the leak. In this way, to the extent that the respiratory airflow signal is of high quality, ventilatory support will be provided as described in the preceding paragraphs, but to the extent that the respiratory airflow signal is of poor quality and it is difficult to synchronize reliably with the patient's efforts, or to know if the patient's 5 efforts are adequate, ventilatory support will be provided in an orderly manner at a predetermined fixed rate.

Assuming that the sleeping subject's PCO_2 is stable at slightly above the subject's chemoreceptor set-point and the airway is open, the system will remain stable.

10 This is explained as follows. The minimum amplitude, A, of $3 \text{ cmH}_2\text{O}$ will be unloading some of the subject's high work of breathing, but is too small to provide all the respiratory work needed to maintain ventilation and PCO_2 at the subject's set-point. Therefore, there will be an error signal from the subject's chemoreceptors. Therefore the subject will be making spontaneous ventilatory efforts (but less than usual), and the upper 15 airway will be patent. Since the target ventilation is only 95% of the spontaneous ventilation, the actual ventilation will be slightly higher than the target ventilation, and the integrator determining amplitude A will remain clipped at the minimum amplitude. If there is a primary reduction in the subject's ventilation of more than 5% due to a primary reduction in ventilatory effort or increase in airway resistance, there will be an immediate 20 and rapid increase in the amplitude A by sufficient to maintain ventilation at a level of at least 95% of the previous spontaneous level, thus preventing hypopneas.

An example is shown schematically in Fig. 6. For the first 4 breaths, the subject 25 is making steady respiratory efforts, and the pressure modulation amplitude A remains at the minimum value of $3 \text{ cmH}_2\text{O}$. Respiratory airflow is due to the combined efforts of subject and ventilation apparatus. At the first vertical line, I, the subject's spontaneous efforts cease. For the next 12 breaths, all respiratory airflow is due only to the machine. The first breath is delivered approximately on schedule, but produces less respiratory airflow than usual, because only the minimum degree of support is provided. Over the 30 next few breaths, the amplitude A quickly to the maximum of $10 \text{ cmH}_2\text{O}$, restoring respiratory airflow to almost its original level. At the second vertical line, II, the subject recommences spontaneous respiratory efforts at the previous level, and the degree of

machine generated support quickly reduces again. It is to be noted in Fig. 6 that during a period of cessation of spontaneous effort, the subject will be ventilated at the preset respiratory rate, due to the operation of fuzzy rule 8. Conversely, during the periods of normal effort, support is provided in phase with the subject's efforts. These may be
5 slower than the preset rate (as in Fig. 6) or they may be faster than the preset rate.

The subject can acutely increase their spontaneous ventilation at will. Transient increases in ventilation for example due to brief arousals will lead to a small degree of hypcapnia, but the resultant secondary reduction or cessation in subject's efforts will
10 again be immediately matched by an increase in amplitude A sufficient to hold ventilation at a level of at least 95% of the previous steady level. Conversely, gradual changes in the subject's chemoreceptor set-point over minutes will result in gradual changes in target ventilation, which will remain at 95% of the subject's actual ventilation. This is shown schematically in Fig. 7. The lower tracing shows respiratory airflow gradually decreasing
15 over a 30 minute period. The calculated recent average ventilation and target ventilation (middle trace) similarly decline over the thirty minutes. However, since the recent average ventilation is always larger than the target ventilation, the degree of support always remains at the minimum (top tracing).

20 An embodiment of the invention was tested in ten patients with severe cardiac failure and Cheyne-Stokes breathing during sleep. The target ventilation was initially set to 5-7.5 L/min, and the end expiratory pressure P_0 was set to 8 cmH₂O. The patients were tested on each one of a control night (no assistance), nasal oxygen at 2 L/min, CPAP (7-10 cmH₂O as tolerated, bi-level CPAP (ResMed VPAP-ST™ machine, with VPAP at 4
25 cmH₂O and IPAP at 12-18 cmH₂O as required, with the backup rate at 2 L/min below the spontaneous rate), and a prototype of the present applicant's Auto CS™ machine.

30 The apnea+hypopnea index (AHI), ASDA microarousal index (ARI), and percentage of time in slow wave (SWS) and REM sleep were calculated using standard procedures. The results are presented as mean \pm sem. The statistical analysis is repeated measures ANOVA after rank transform.

	Control	Oxygen	CPAP	VPAP-ST	Auto CS
AHI (hr ⁻¹)	43.3±3.5 ⁺	24.8±3.2 ⁺	24.1±3.4 ⁺	9.0±1.3*	4.8±0.9
ARI (hr ⁻¹)	48.1±3.6 ⁺	34.7±4.5 ⁺	30.8±3.5 ⁺	18.4±3.4	14.5±2.6
SWS (%)	13.7±2.8	19.8±2.6	19.3±3.5	20.8±3.0	21.1±2.7
REM (%)	10.5±2.1 ⁺	13.3±2.4	12.2±1.6*	15.3±2.3	18.4±0.6

*Auto CS P<0.05, ⁺ Auto CS P<0.01.

In most subjects, transcutaneous PCO₂ fell by approximately 5-10 mmHg
 10 due to a period of hyperventilation in the first few minutes of awake breathing. This resulted in some instability of the upper airway and residual mild Cheyne-Stokes breathing for the first 20-40 minutes of sleep. Subsequently, Cheyne-Stokes breathing was largely abolished. Fig. 4 shows the same subject as Fig. 1, also in stage 3 non-REM sleep, but this time using the new device. The mask pressure swings are broadly
 15 comparable with those in Fig. 1, but very small changes with time can be seen, as the device opposes any changes in the subject's ventilation. It is clear that the subject's ribcage movement (ie. measured using a thoracic respiratory band) and oxygen saturation (SaO₂) are greatly stabilized compared with Fig. 1, and Cheyne-Stokes breathing has been eliminated.

20

In some subjects, the period of unstable breathing immediately after sleep onset could be eliminated by asking the subject to remain awake for 20 minutes after applying the mask and before going to sleep, in order to minimize overbreathing immediately prior to sleep onset.

CLAIMS:

1. A method for treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising the steps of:

- 5 providing a subject with ventilatory support;
deriving a measure of the subject's instantaneous ventilation; and
adjusting the degree of ventilatory support to reduce changes in said measure of
instantaneous ventilation over a timescale similar to that of the waxing-waning cycle of
untreated Cheyne-Stokes breathing or central sleep apnea, while allowing changes in said
10 measure of instantaneous ventilation over a timescale much longer than said waxing-
waning cycle.

[Signature] 2. A method for treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising the steps of:

- 15 providing a subject with ventilatory support;
deriving a measure of the subject's instantaneous ventilation;
deriving a measure of the subject's longterm average ventilation;
setting the controlled variable of a servo-controller to a function of said measure
of the subject's instantaneous ventilation;
20 setting the reference variable of said servo-controller to a measure of the
subject's longterm average ventilation; and
adjusting the magnitude of said ventilatory support in accordance with the output
of said servo-controller.

25 3. A method for treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising the steps of:

- providing a subject with ventilatory support;
deriving a measure of the subject's instantaneous ventilation;
high pass filtering said measure of the subject's instantaneous ventilation; and
30 adjusting the degree of said ventilatory support inversely with said high pass
filtered measure of the subject's instantaneous ventilation.

4. A method as claimed in claim 1, whereby the step of adjusting the degree of ventilatory support comprises the steps of:

low pass filtering said measure of instantaneous ventilation to derive a measure of longterm average ventilation;

5 setting a target signal equal to a fraction of said measure of longterm average ventilation; and

servo-controlling said measure of instantaneous ventilation to at least equal the target ventilation.

10 5. A method as claimed in any one of the preceding claims, whereby ventilatory support is positive pressure ventilatory support.

15 6. A method as claimed in claim 5, whereby the degree of ventilatory support is the difference between a peak inspiratory pressure and an end expiratory pressure.

7. A method as claimed in any one of the preceding claims, whereby deriving a measure of instantaneous ventilation comprises at least the steps of:

20 deriving a signal proportional to the subject's respiratory airflow; and rectifying said signal.

25 8. A method as claimed in any one of the preceding claims, whereby the degree of ventilatory support provided is clipped to exceed a minimum degree of support, chosen to be less than the degree of support that would perform the subject's entire work of breathing.

30 9. A method as claimed in any one of the preceding claims, whereby the degree of ventilatory support provided is clipped to not exceed a maximum degree of support, chosen to be sufficient to perform most or all of the subject's work of breathing, but not sufficient to be dangerous.

10. A method as claimed in any one of the preceding claims, including the further steps of:

the severity of reduction in ventilation is determined;

5 if the severity of reduction in ventilation is high, then said ventilatory support is provided at a preset rate;

if the severity of reduction in ventilation is zero, then said ventilatory support is provided in phase with the subject's respiratory airflow; and

for intermediate degrees of severity of reduction in ventilation, support is provided at an intermediate rate.

10

11. A method as claimed in claim 10, whereby the severity of reduction in ventilation is calculated by comparing the subject's ventilation with a low pass filtered ventilation.

15

12. Apparatus for the treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising:

a device for providing ventilatory support of controllable magnitude;

means for deriving a signal indicative of instantaneous ventilation of a subject; and

20

a servo-controller operable to control the degree of ventilatory support provided by said ventilatory support device to oppose short-term changes in said measure of instantaneous ventilation, but permit longterm changes in said measure of instantaneous ventilation.

25

13. Apparatus as claimed in claim 12, wherein the ventilatory support device provides positive pressure ventilatory support.

14. Apparatus for treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising:

30

a controllable source of breathable gas at positive pressure;

means for delivering said breathable gas at positive pressure to a subject's airway;

means for deriving a measure of the subject's instantaneous ventilation; and
a servo-controller for adjusting the degree of ventilatory support to reduce
changes in said measure of instantaneous ventilation over a timescale similar to that of the
waxing-waning cycle of untreated Cheyne-Stokes breathing or central sleep apnea, while
5 allowing changes in said measure of instantaneous ventilation over a timescale much
longer than said waxing-waning cycle.

15. Apparatus for treatment of cardiac failure, Cheyne-Stokes breathing or
central sleep apnea, comprising:

- 10 a controllable source of breathable gas at positive pressure;
- means for delivering said breathable gas at positive pressure to a subject's
airway;
- means for deriving a measure of the subject's instantaneous ventilation;
- means for deriving a measure of the subject's longterm average ventilation;
- 15 means for deriving a target ventilation as a function of said measure of the
subject's longterm average ventilation;
- a servo-controller, whose input variable is a function of said measure of the
subject's instantaneous ventilation, and whose reference variable is said target ventilation;
and
- 20 means for adjusting the magnitude of said ventilatory support according to the
output of the servo-controller.

16.

Apparatus as claimed in any one of claims 12 to 15, wherein said
measure of instantaneous ventilation is proportional to the absolute value of the
respiratory airflow.

17.

Apparatus as claimed in claim 15, wherein said measure of the subject's
recent average ventilation is proportional to the low pass filtered absolute value of the
respiratory airflow, said low pass filter having a time constant of the order of, or longer
than the waxing-waning cycle of untreated Cheyne-Stokes breathing.

18. Apparatus for treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising:

a controllable source of breathable gas at positive pressure;

means for delivering said breathable gas at positive pressure to a subject's airway;

means for deriving a measure of the subject's instantaneous ventilation;

means for high pass filtering said measure of the subject's instantaneous ventilation; and

10 a servo-controller whose input variable is a function of said high pass filtered measure of the subject's instantaneous ventilation, and which adjusts the magnitude of said ventilatory support inversely with said high pass filtered measure of the subject's instantaneous ventilation.

19. Apparatus as claimed in claim 18, wherein said high pass filter has a time constant of the order of or longer than the waxing-waning cycle of untreated Cheyne-Stokes breathing.

20. Apparatus as claimed in either one of claim 17 or claim 19, wherein said time constant is 100 seconds.

20

21. Apparatus as claimed in claim 15, wherein said target ventilation is a chosen fraction of the subject's recent average ventilation.

22. Apparatus as claimed in claim 15, wherein the servo-control means is operable to servo-control said measure of instantaneous ventilation to at least equal the target ventilation.

23. Apparatus as claimed in either one of claim 15 or claim 22, wherein the servo-control means is operable to increase the degree of support if said measure of instantaneous ventilation is less than said target ventilation, and reduce the degree of support if said measure of instantaneous ventilation is greater than said target ventilation.

24. Apparatus as claimed in any one of claims 12 to 23, wherein the servo-control means is further operable to clip the degree of ventilatory support to exceed a minimum degree of support, chosen to be less than the degree of support that would perform a subject's entire work of breathing.

5

25. Apparatus as claimed in any one of claims 12 to 23, wherein the servo-control means is operable to modulate said positive said pressure in phase with respiratory air flow where the subject is breathing adequately, and to modulate said positive pressure at a preset rate where the subject is not breathing adequately.

10

26. Apparatus as claimed in claim 25, wherein the servo-control means is operable to assess the adequacy of breathing by comparing a measure of instantaneous ventilation with a target ventilation.

15

27. A method for the treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising the steps of:

providing a subject with positive pressure ventilatory support, with controllable amplitude and rate;

deriving a measure of the subject's instantaneous ventilation;

20

adjusting said amplitude of positive pressure by:

(a) low pass filtering said measure of instantaneous ventilation to derive a measure of recent average ventilation;

(b) setting a target ventilation equal to a fraction of said measure of recent average ventilation; and

25 (c) servo-controlling said measure of instantaneous ventilation to at least equal the target ventilation, by adjusting the degree of ventilatory support;

and

continuously adjusting said rate by:

30

(a) to the extent that the instantaneous ventilation equals or exceeds said target ventilation, modulating said positive pressure in phase with respiratory airflow; and

(b) to the extent that the instantaneous ventilation is less than said target ventilation, modulating said positive pressure at a pre-set rate.

5 28. Apparatus for the treatment of cardiac failure, Cheyne-Stokes breathing or central sleep apnea, comprising:

ventilator means for providing ventilatory support with controllable amplitude and rate;

10 sensor and processing means for deriving a signal indicative of instantaneous ventilation of a subject; and

servo-control means operable to adjust the amplitude of the pressure support by low pass filtering said instantaneous ventilation signal to derive a measure of recent average ventilation, setting a target ventilation equal to a fraction of said measure of recent average ventilation, and servo-controlling said measure of instantaneous ventilation 15 to at least equal the target ventilation, and further operable to continuously adjust said rate by modulating said positive pressure in phase with respiratory airflow to the extent that the instantaneous ventilation equals or exceeds said target ventilation, and modulating said positive pressure at a pre-set rate to the extent that the instantaneous ventilation is less than said target ventilation.

20

29. A method for treatment of cardiac failure, Cheyne Stokes breathing or central sleep apnea, comprising the steps of:

providing a subject with ventilatory support;

deriving a measure of instantaneous ventilation; and

25 adjusting the degree of ventilatory support to oppose short term changes in said measure of instantaneous ventilation, but permitting longterm changes in said measure of instantaneous ventilation.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU 99/00386

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member				
(To put a line under the citations tab to the first point on the next row and press F8)							
WO	9211054	AU	59270/90	AU	40711/95	US	5259373
		AU	82154/91	AU	63717/98	US	5549106
		AU	33877/93	EP	563044	US	5794614
		AU	48748/93	EP	472664	US	5845636
		AU	34471/95	US	5134995	WO	9014121
WO	9812965	AU	37623/97	EP	929336	WO	9806449
		AU	41933/97				
END OF ANNEX							

(To add more lines press TAB at end of last row, remove paragraph marker to join up 'END OF ANNEX' box)